Liver Disease Clinical Trials in Los Angeles

Showing 21-40 of 68 trials

Nonalcoholic Fatty Liver Disease (NAFLD) Database 3

NCT04454463

The NAFLD Database 3 will enroll approximately 1500 adult patients and 750 pediatric patients suspected or known to have NAFLD or NASH-related cirrhosis. To elucidate, through the cooperative effort of a multidisciplinary and multicenter group of collaborators, the etiology, natural history, diagnosis, treatment, and prevention of NAFLD, and in particular its more severe form of NASH and its complications.

Liver Diseases

Johns Hopkins Bloomberg School of Public Health1,649 participantsStarted Nov 2020

La Jolla, California, United States • Los Angeles, California, United States • San Diego, California, United States +13 more locations

Active Not RecruitingPhase 3< 1 mile

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

NCT04951219

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)

Non-Alcoholic Fatty Liver Disease

Madrigal Pharmaceuticals, Inc.1,000 participantsStarted Jul 2021

Birmingham, Alabama, United States • Chandler, Arizona, United States • Chandler, Arizona, United States +68 more locations

Nonalcoholic Fatty Liver Disease (NAFLD) Database 3

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

Liver Disease Trials in Other Cities

Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions

Alcoholic Liver Disease and the Gut Microbiome

Clinical Trial Multi-analyte Blood Test

A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury

Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)

Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis

Goals of Care Conversations Study

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.

Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation

Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US

A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).

An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)

Communication During Hospitalization About Resuscitation Trial

Other Conditions in Los Angeles